clodronic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium metabolism regulator, pharmaceutical aid	690	10596-23-3

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clodronic acid
clodronate
dichloromethylenediphosphonic acid
methanedichlorodiphosphonic acid

A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.

Molecular weight: 244.88
Formula: CH4Cl2O6P2
CLOGP: -0.95
LIPINSKI: 0
HAC: 6
HDO: 4
TPSA: 115.06
ALOGS: -1.52
ROTB: 2

Drug dosage:

Dose	Unit	Route
1.60	g	O
1.50	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	7.47 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	80 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.88 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.64 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	43.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1986	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteonecrosis of jaw	79.05	68.33	21	316	35102	63453583

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteonecrosis of jaw	114.19	65.97	29	372	43197	79700790

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M05BA02	MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Bisphosphonates
MeSH PA	D050071	Bone Density Conservation Agents
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50646	antiosteoporotic

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

Species	Use	Relation
Horses	Navicular syndrome	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Osphos	Dechra, Ltd.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.13	acidic
pKa2	4.2	acidic
pKa3	5.18	acidic
pKa4	9.25	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
ADP/ATP translocase 2	Enzyme	P05141	ADT2_HUMAN					WOMBAT-PK
ADP/ATP translocase 1	Transporter	P12235	ADT1_HUMAN					WOMBAT-PK
ADP/ATP translocase 3	Enzyme	P12236	ADT3_HUMAN					WOMBAT-PK
Tyrosine-protein phosphatase non-receptor type 1	Enzyme	P18031	PTN1_HUMAN					WOMBAT-PK
Solute carrier family 17 member 9	Transporter	Q9BYT1	S17A9_HUMAN	INHIBITOR	IC50	7.81		IUPHAR
Type IV secretion-like conjugative transfer relaxase protein TraI	Unclassified		B1LRJ1_ECOSM		Ki	8.52		CHEMBL

External reference:

ID	Source
N0000166424	NUI
D03545	KEGG_DRUG
3350	RXNORM
C0012081	UMLSCUI
CHEBI:110423	CHEBI
CHEMBL12318	ChEMBL_ID
DB00720	DRUGBANK_ID
D004002	MESH_DESCRIPTOR_UI
25419	PUBCHEM_CID
9605	IUPHAR_LIGAND_ID
4147	INN_ID
0813BZ6866	UNII
003710	NDDF
387579006	SNOMEDCT_US
418080006	SNOMEDCT_US
768528000	SNOMEDCT_US

Pharmaceutical products:

None